NECCR Primacare Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$39,187	2
2022	Research	$159	1
2021	Research	$9,482	1
2020	Research	$56,034	1
2019	Research	$50,130	4

Breakdown

Who paid Research payments · program years 2019–2023

E.R. Squibb & Sons, L.L.C. $110,184 6 payments
Cue Health Inc. $39,000 1 payment
Gilead Sciences, Inc. $5,807 2 payments

Studies the money was for Research payments · program years 2019–2023

Phase IIB Study - F3 24 wk $56,034 1 payment
Influenza $39,000 1 payment
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Stage 3 Liver Fibrosis $34,855 1 payment
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis $9,482 1 payment
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Compensated Liver Cirrhosis $9,468 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis $5,750 1 payment
Phase IIB in NASH mono - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH) $346 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis $57 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.